Iain Macphee

List of Publications by Year
in descending order

49 papers	2,237 citations	304368 22 h-index	223531 46 g-index
50 all docs	50 docs citations	50 times ranked	2384 citing authors

#	Article	IF	Citations
1	Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extendedâ€release tacrolimus preparation. Clinical and Translational Science, 2022, 15, 70-78.	1.5	8
2	Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney International Reports, 2021, 6, 2803-2810.	0.4	7
3	Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy. EBioMedicine, 2020, 58, 102899.	2.7	16
4	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. American Journal of Transplantation, 2019, 19, 2262-2273.	2.6	13
5	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
6	Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study. American Journal of Transplantation, 2018, 18, 1370-1379.	2.6	47
7	Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantation. Molecular and Cellular Endocrinology, 2018, 473, 205-216.	1.6	8
8	Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?. American Journal of Transplantation, 2016, 16, 3443-3457.	2.6	92
9	Cardiac and vascular changes with kidney transplantation. Indian Journal of Nephrology, 2016, 26, 1.	0.2	22
10	Do statins prevent acute kidney injury?. Expert Opinion on Drug Safety, 2015, 14, 1547-1561.	1.0	7
11	Patient involvement in selection of immunosuppressive regimen following transplantation. Patient Preference and Adherence, 2014, 8, 1705.	0.8	11
12	Xenobiotic Metabolism: The Effect of Acute Kidney Injury on Non-Renal Drug Clearance and Hepatic Drug Metabolism. International Journal of Molecular Sciences, 2014, 15, 2538-2553.	1.8	43
13	The effects of acute renal failure on drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 11-23.	1.5	40
14	HLA Antibodyâ€“Incompatible Kidney Transplantation Between Jehovah's Witnessesâ€”A Case Report. Transplantation Proceedings, 2013, 45, 2069-2071.	0.3	3
15	UK Renal Registry 15th Annual Report: Chapter 3 Demographic and Biochemistry Profile of Kidney Transplant Recipients in the UK in 2011: National and Centre-Specific Analyses. Nephron Clinical Practice, 2013, 123, 55-80.	2.3	7
16	CYP3A5 Genotype Had no Impact on Intrapatient Variability of Tacrolimus Clearance in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2013, 35, 328-331.	1.0	30
17	A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. British Journal of Clinical Pharmacology, 2013, 76, 425-431.	1.1	32
18	Renohepatic crosstalk: does acute kidney injury cause liver dysfunction?. Nephrology Dialysis Transplantation, 2013, 28, 1634-1647.	0.4	75

#	Article	IF	Citations
19	Generic Tacrolimus in Renal Transplantation. Transplantation, 2012, 93, e45-e46.	0.5	9
20	Pharmacogenetic biomarkers: cytochrome P450 3A5. Clinica Chimica Acta, 2012, 413, 1312-1317.	0.5	32
21	Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. Pharmacogenomics and Personalized Medicine, 2012, 5, 63.	0.4	11
22	European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive Drugs. Transplant International, 2011, 24, 1135-1141.	0.8	65
23	Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2579-2586.	2.2	27
24	Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation. Therapeutic Drug Monitoring, 2011, 33, 178-184.	1.0	36
25	Use of Pharmacogenetics to Optimize Immunosuppressive Therapy. Therapeutic Drug Monitoring, 2010, 32, 261-264.	1.0	17
26	Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrology Dialysis Transplantation, 2010, 25, 628-634.	0.4	25
27	Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 761-771.	1.5	11
28	Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Medicine, 2009, 35, 1271-1275.	3.9	20
29	BK Virus Nephropathy in Renal Transplant Patients in London. Transplantation, 2008, 85, 1008-1015.	0.5	27
30	A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 Genotype. Transplantation, 2008, 85, 163-165.	0.5	49
31	Enlarged kidneys and acute renal failure why is a renal biopsy necessary for diagnosis and treatment?. Nephrology Dialysis Transplantation, 2007, 23, 401-403.	0.4	11
32	Tacrolimus Dose in Black Renal Transplant Recipients. Transplantation, 2007, 83, 997-999.	0.5	25
33	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opinion on Pharmacotherapy, 2007, 8, 2045-2058.	0.9	22
34	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clinical Transplantation, 2007, 21, 252-257.	0.8	31
35	Paradoxical Response to Tacrolimus Assessed by Interleukin-2 Gene Expression. Transplantation Proceedings, 2006, 38, 3327-3330.	0.3	4
36	Page kidney: successful radiological management of acute renal failure. Nephrology Dialysis Transplantation, 2006, 21, 1740-1740.	0.4	16

#	Article	IF	Citations
37	Blockade of OX40-ligand after initial triggering of the T helper 2 response inhibits mercuric chloride-induced autoimmunity. Immunology, 2006, 117, 402-408.	2.0	5
38	Compromise of renal transplant blood flow by an arteriovenous graft. Nephrology Dialysis Transplantation, 2006, 21, 2644-2646.	0.4	2
39	Proteinuria in 3 sequential pregnancies following a fourth renal transplant. Journal of Nephrology, 2006, 19, 828-30.	0.9	1
40	Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. Transplantation, 2005, 79, 499-502.	0.5	178
41	CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay. Clinical Chemistry, 2005, 51, 2214-2215.	1.5	10
42	Genotyping cytochrome P450 3A5 using the Light Cycler. Annals of Clinical Biochemistry, 2005, 42, 376-381.	0.8	19
43	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. Expert Opinion on Pharmacotherapy, 2005, 6, 2593-2605.	0.9	9
44	The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation. American Journal of Transplantation, 2004, 4, 914-919.	2.6	238
45	The Pharmacogenetics of Immunosuppression for Organ Transplantation. Molecular Diagnosis and Therapy, 2003, 3, 291-301.	3.3	28
46	Burkholderia pseudomallei infection, or melioidosis, and nephrotic syndrome. Nephrology Dialysis Transplantation, 2002, 17, 137-139.	0.4	11
47	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation, 2002, 74, 1486-1489.	0.5	283
48	Prophylaxis of cytomegalovirus infection in renal transplantation. Nephrology Dialysis Transplantation, 2001, 16, 2276-2279.	0.4	5
49	The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology, 1990, 70, 1-5.	2.0	175